|Articles|March 1, 2004

Etanercept shows safety, efficacy through five years

Washington -- A new study presented in poster form at the recent AAD meeting concludes that etanercept continues to post an excellent record for the treatment of rheumatoid arthritis. The drug maintains its safety profile and clinical efficacy for treatment durations of more than five years.

Newsletter

Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.


Latest CME